Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2021. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 4579739010 | Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 4579740012 | Product containing precisely carbidopa anhydrous (as carbidopa) 25 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg oral tablet | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
| Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg oral tablet | Is a | Product containing only carbidopa and levodopa in oral dose form (medicinal product form) | true | Inferred relationship | Some | ||
| Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg oral tablet | Has precise active ingredient | Levodopa (substance) | true | Inferred relationship | Some | 1 | |
| Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 2 | |
| Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg oral tablet | Plays role | Antiparkinson therapeutic role | true | Inferred relationship | Some | ||
| Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
| Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg oral tablet | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 2 | |
| Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg oral tablet | Has basis of strength substance (attribute) | Carbidopa anhydrous | true | Inferred relationship | Some | 2 | |
| Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg oral tablet | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
| Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg oral tablet | Has precise active ingredient | Carbidopa | true | Inferred relationship | Some | 2 | |
| Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg oral tablet | Has manufactured dose form | Oral tablet | true | Inferred relationship | Some | ||
| Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg oral tablet | Has basis of strength substance (attribute) | Levodopa (substance) | true | Inferred relationship | Some | 1 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR